All AbMole products are for research use only, cannot be used for human consumption.
Tofacitinib citrate inhibits IL-2-mediated human T cell blast proliferation and IL-15-induced CD69 expression with IC50 of 11 nM and 48 nM, respectively. Tofacitinib citrate prevents mixed lymphocyte reaction with IC50 of 87 nM. Tofacitinib citrate inhibits interleukin-6-induced phosphorylation of STAT1 and STAT3 with IC50 of 23 nM and 77 nM, respectively. Tofacitinib citrate decrease a delayed-type hyper-sensitivity response and extended cardiac allograft survival in murine models. CP-690,550 induced a significant pro-apoptotic effect on murine FDCP-EpoR cells carrying JAK2(V617F), whereas a lesser effect was observed for cells carrying wild-type JAK2.
J Virol. 2020 Feb 14;94(5):e01791-19.
Targeting Kaposi's Sarcoma-Associated Herpesvirus ORF21 Tyrosine Kinase and Viral Lytic Reactivation by Tyrosine Kinase Inhibitors Approved for Clinical Use
Tofacitinib citrate purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | FDCP-EpoR JAK2WT and JAK2V617F cell lines |
Preparation method | Using identical culture conditions for both FDCP-EpoR JAK2WT and JAK2V617F cell lines perform determination of growth inhibition by Tofacitinib citrate is performed. Briefly, culturing 1 × 105 cells/mL in 96-well flat-bottom plates at 37 °C in a humidified 5% CO2 atmosphere using RPMI 1640 supplemented with 1.25% FCS, and 5% WEHI supernatant. It's necessary to prevent binding between Tofacitinib citrate and serum proteins to decrease FCS concentration . Terminating growth inhibition assays by addition of 20 μL CellTiter96 One Solution Reagent. Incubating Flat-bottom plates for an additional 3 hours for MTT assay. Determining absorbance at 595 nm on a BioTek Synergy-HT microplate reader. Results are the average standard deviation of three independent determinations. |
Concentrations | 0-4 μM |
Incubation time | 72 hours |
Animal Experiment | |
---|---|
Animal models | Mauritius-origin adult cynomolgus monkeys |
Formulation | 0.5% methylcellulose in distilled water |
Dosages | 10, 30 mg/kg/d |
Administration | Oral gavage |
Molecular Weight | 504.49 |
Formula | C22H28N6O8 |
CAS Number | 540737-29-9 |
Solubility (25°C) | DMSO >30 mg/mL Water 2 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Related JAK Products |
---|
iJak-381
iJak-381 is a JAK1/2 inhibitor with anti-inflammatory activity. |
Ritlecitinib (malonate)
Ritlecitinib (PF-06651600) malonate is an orally active and selective JAK3 inhibitor with an IC50 of 33.1 nM. |
Deuruxolitinib
Deuruxolitinib is a deuterated Ruxolitinib (INCB18424), which modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research of hair loss disorders. |
A-005
A-005 is a potentially first-in-class, brain-penetrating TYK2 allosteric inhibitor for studies related to neuroinflammatory and neurodegenerative diseases. |
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.